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Objective: Anti-catabolic disease modifying drugs (DMOADs) aim to reduce cartilage loss in knee oste-
oarthritis (KOA). Testing such drugs in clinical trials requires sufﬁcient rates of loss in the study partic-
ipants to occur, preferably at a mild disease stage where cartilage can be preserved. Here we analyze a
“progression” model in mild radiographic KOA (RKOA), based on contra-lateral radiographic status.
Methods: We studied 837 participants (62.4 ± 9 yrs; 30 ± 4.9 kg/m2; 61.8% women) from the Osteoar-
thritis Initiative (OAI) with mild to moderate RKOA (Kellgren Lawrence grade [KLG] 2e3) and with/
without Osteoarthritis Research Society International (OARSI) atlas radiographic joint space narrowing
(JSN). These had quantitative measurements of subregional femorotibial cartilage thickness from mag-
netic resonance imaging (MRI) at baseline and 1-year follow-up. They were stratiﬁed by contra-lateral
knee status: no (KLG 0/1), deﬁnite (KLG2) and moderate RKOA (KLG 3/4).
Results: KLG2 knees with JSN and moderate contra-lateral RKOA had (P ¼ 0.008) greater maximum
subregional cartilage loss 220 mm [95% conﬁdence interval (CI) 255, 184 mm] than those without
contra-lateral RKOA 164 mm [187, 140 mm]. Their rate of subregional cartilage loss was similar and
not signiﬁcantly different (P ¼ 0.61) to that in KLG 3 knees without contra-lateral RKOA (232 mm;
[266; 198 mm]). The effect of contra-lateral RKOA status was less in KLG2 knees without JSN, and in
KLG3 knees.
Conclusion: KLG2 knees with JSN and moderate contra-lateral RKOA, display relatively high rates of
subregional femorotibial cartilage loss, despite being at a relatively mild stage of RKOA. They may
therefore provide a unique opportunity for recruitment in clinical trials that explore the efﬁcacy of anti-
catabolic DMOADs on structural progression.
© 2014 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Only symptomatic treatment is currently available for osteoar-
thritis (OA), and this has been found to have only small to moderate
effects1. Efforts in developing disease-modifying OA drugs
(DMOADs) have yet had little success2e4. However, in the interest of
delaying surgical replacement of the knee5, treatment that is
effective in reducing or even stopping structural change andto: S. Cotofana, Institute of
tria. Tel: 43-662-2420-80410;
otofana).
ternational. Published by Elsevier Lprogression is highly desirable6. Anti-catabolic DMOADs are
designed to reduce cartilage loss or other structural alterations in
knee OA. Testing such drugs in clinical trials requires sufﬁcient rates
of cartilage loss in the study participants (i.e., in the placebo group)
in order to demonstrate drug efﬁcacy, preferably at a mild phase of
the disease where as much cartilage can be preserved as possible.
Further, it has been suspected that mild stages of radiographic knee
OA (RKOA), i.e., Kellgren and Lawrence7 grades (KLG) 2 may be
more amenable to anti-catabolic DMOADs compared to more
advanced stages (KLG  3), because the vicious circle of tissue
degradation and increasing mechanical challenges is still at an mild
phase8e11.
There is recent consensus that knees with moderate RKOA
(KLG  3) display greater cartilage loss than those with relativelytd. All rights reserved.
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that the rate of cartilage loss in knees without radiographic joint
space narrowing (JSN) was indistinguishable from that in healthy
reference participants without RKOA or risk factors of RKOA16,17.
This provides a certain dilemma, because knees at a mild stage of
RKOA, in whom anti-catabolic DMOAD may be potentially most
successful, do generally not show sufﬁcient cartilage loss (pro-
gression) for a clinical trial to demonstrate structural efﬁcacy of a
DMOAD over a 1- or 2-year observational period. Therefore, an
indicator of fast progression in knees that still are at a relatively
mild stage of diseasewould be very helpful in the design of DMOAD
trials.
Idiopathic knee OA is thought to represent a bilateral disease,
and several studies reported higher rates of incident RKOA when
the contra-lateral knee displayed deﬁnite radiographic change
before incidence occurred in the other knee18e20. RKOA in one knee,
in the absence of the relevant trauma history, may indicate a certain
intrinsic susceptibility to develop RKOA in the other knee, poten-
tially comparable to an osteoporotic fracture that indicates an
increased risk of skeletal fragility and risk of subsequent fractures at
other locations21,22. The same relationship may also exist in the
context of structural progression of RKOA, i.e., cartilage loss being
greater in knees having a contra-lateral knee at a moderate stage
when compared to knees having a contra-lateral knee free of
disease.
The purpose of this study was therefore to investigate the
impact of the contra-lateral RKOA status on the rate of progres-
sion (i.e., quantitative cartilage loss) in knees with existing RKOA.
We hypothesized that mild RKOA knees with moderate contra-
lateral RKOA have higher rates of progression than those
without contra-lateral RKOA, and therefore may be useful in
DMOAD trials.Table I
Baseline demographic, clinical and imaging data of the participants with 1-year
(n ¼ 837) and 2-year (n ¼ 487) follow-up
KLG and JSN of investigated knee
KLG2 without JSN KLG2 with JSN KLG3
n ¼ 158 n ¼ 339 n ¼ 340
Age (SD) 60.3 (8.6) 61.9 (9.2) 63.9 (8.7)
Females (%) 119 (75.3) 213 (62.8) 185 (54.4)
BMI (SD) 30.1 (4.7) 29.9 (5.1) 30.1 (4.8)
Side of investigated knee
Right (%) 126 (79.7) 273 (80.5) 258 (75.9)
Previous injury in contra-lateral knee
Count (%) 37 (23.4) 97 (28.6) 90 (26.5)
Previous injury in investigated knee
Count (%) 47 (29.7) 123 (36.3) 142 (41.8)
MR sequence of investigated knee
DESS (%) 60 (38.0) 126 (37.2) 177 (52.1)
FLASH (%) 98 (62.0) 213 (62.8) 163 (47.9)Methods
The Osteoarthritis Initiative (OAI)
The data used for this investigation was taken from the
OAI (www.oai.ucsf.edu)13. The OAI is a multi-center, prospective
observational cohort study, with the purpose of improving public
health through the prevention or alleviation of pain and disability
from knee OA. 4796 individuals were included who were 45e79
years old, had an almost equal distribution between men and
women, and included several ethnicities. Participants were evalu-
ated annually by clinical examination on their knee status and knee
joint imaging, i.e., X-ray23,24 and MR imaging techniques13,25.
General exclusion criteria were the presence of rheumatoid
arthritis or other inﬂammatory arthritis, bi-lateral end-stage knee
OA, inability to walk without aids and contradictions to imaging
techniques.Presence of JSN in investigated knee
Medial (%) 0 278 (82.0) 257 (75.6)
Lateral (%) 0 67 (19.8) 95 (27.9)
KLG of contra-lateral knee
0 (%) 18 (11.4) 42 (12.4) 52 (15.3)
1 (%) 29 (18.4) 58 (17.1) 44 (12.9)
2 (%) 89 (56.3) 148 (43.7) 99 (29.1)
3 (%) 18 (11.4) 70 (20.6) 114 (33.5)
4 (%) 4 (2.5) 21 (6.2) 31 (9.1)
Mean 1-year change in
cartilage thickness
n ¼ 158 n ¼ 339 n ¼ 340
OV one/mm (SD) 153 (133) 183 (143) 243 (166)
FTJ/mm (SD) 35.2 (209) 54.8 (186) 123 (230)
Mean 2-year change in
cartilage thickness
n ¼ 89 n ¼ 196 n ¼ 202
OV one/mm (SD) 179 (97) 213 (150) 358 (234)
FTJ/mm (SD) 47.9 (164) 77.7 (211) 242 (302)Sample selection
The participants included in the current study were selected
from the OAI according to the following criteria:
a) Availability of quantitative measurements of subregional fem-
orotibial cartilage thickness at baseline, 1-year (and 2-year)
follow-up, obtained from coronal fast low angle shot (FLASH)
images26 or from double echo steady state (DESS) images with
water excitation13
b) Availability of central radiographic readings for both knees at
baseline, 1-year and at the 2-year follow-up survey (release
version 0.2.2)c) Presence of (deﬁnite) RKOA at baseline (i.e., KLG  2), but not
end-stage RKOA (i.e., KLG4), in the central readings for the ipsi-
lateral (investigated) knee using MRI
According to the above selection criteria, 837 knees from 837
individuals (age 62.4±9 yrs; bodymass index [BMI] 30 ± 4.9 kg/m2;
61.8% females) were available with baseline and 1-year follow-up
data, and 487 knees from 487 individuals (age 62.3 ± 9 yrs; BMI
29.8 ± 4.8 kg/m2; 60.8% females) had baseline and 2-year follow-up
data (Table I).Radiographic readings
The X-ray acquisitions relied on posteroanterior weight bearing
ﬁxed-ﬂexion radiographs obtainedwith a Synaﬂexer frame (Synarc,
San Francisco, California, USA)23,24. In the present analysis the
central radiographic readings (release 0.5) were performed by
three expert radiologists or rheumatologists at Boston University
(PA, BS, DTF) (https://oai.epi-ucsf.org/datarelease/SASDocs/kXR_
SQ_BU_descrip.pdf) assigning KL grades pertinent to the original
KL description7. The readers were blinded to clinical data and to
follow-up time point. Individual radiographic features including
JSN were scored 0e3 using the Osteoarthritis Research Society In-
ternational (OARSI) atlas27. Knees with presence of deﬁnite osteo-
phytes were graded as KLG2. Those with presence of moderate
multiple osteophytes, deﬁnite JSN, subchondral sclerosis, and
(possible) deformity of the bone were graded as KLG3.
For classiﬁcation of the ipsi-lateral (investigated) KLG2 knees
into those with and into those KLG2 knees without JSN we com-
bined the KL scores (central readings) with the OARSI atlas JSN
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knees without JSN” refers to knees with KL grade 2 and additional
OARSI atlas JSN score¼ 0 and “KLG2 knees with JSN” refers to knees
with KL grade 2 and additional OARSI atlas JSN score  1.
MR imaging analysis
Details of the OAI MRI protocol acquisition parameters can be
found on the OAI webpage www.oai.ucsf.edu and have been pre-
viously described in detail. The MR images were shipped from the
OAI coordinating center to the cartilage analysis center (Chondro-
metrics GmbH, Ainring, Germany). After initial quality control,
manual segmentation of the tibial and weight-bearing femoral
cartilagewas performed by 12 readers with thorough experience in
quantitative cartilage analysis. The readers were blinded to the
aims of the study, to the clinical and radiographic status of the
knees studied, and to acquisition order. The test-retest precision of
the knee cartilage measurement methodology has been reported
previously28,29. All segmentations were quality controlled by one
expert reader.
The mean cartilage thickness was computed for the medial and
lateral tibia (MT/LT) and the weight-bearing aspect of the medial
and lateral femur (cMF/cLF)30. Further, thickness was computed in
16 subregions, ﬁve tibial ones and three femoral ones in each
compartment31e34. Medial femorotibial (MFTC), lateral femoroti-
bial (LFTC), and total femorotibial joint (FTJ) cartilage thickness was
computed as sums of the femorotibial plates. The reproducibility of
cartilage thickness measures for cartilage plates has been reported
to range from 22 to 37 mm, and those in femorotibial subregions
from 19 to 84 mm31. An ordered value (OV) approach was used to
determine the non-location speciﬁc magnitude of cartilage loss in
the one (of 16) subregion in each knee in which the greatest loss
occurred (in mm), i.e., OV one16,17,35,36.
The within-subject and within-group consistency of cartilage
thickness change over one- and 2-year and longer observation
periods in this sample have been reported previously14. Whereas
rates of change in the second year were reported to be somewhat
greater than those in the ﬁrst year, those in the second 2-year
period were of similar magnitude as those in the ﬁrst 2-year
period37.
Statistical analysis
All statistical analyses were performed using SPSS Statistics 21
(IBM, Armonk, NY, USA). Participants were stratiﬁed by ipsi-lateral
knee (i.e., the knee in which cartilage loss was studied with MRI)
radiographic status based on X-ray readings according to the KL
classiﬁcation (for KL grades) and on the OARSI atlas27 (for JSN
grades) into KLG2 without JSN, KLG2 with JSN, or KLG3. In each of
these strata, knees were further stratiﬁed by contra-lateral knee
radiographic status, to either have “no” (deﬁnite) RKOA (KLG0 or 1),
“deﬁnite” RKOA (KLG2) or “moderate” RKOA (KLG3 or 4) in the
other knee (not studied by MRI). Because the purpose of the study
was to identify subjects with mild RKOA with an increased chance
of progression, and because it was shown previously that KLG2
knees without JSN did not show relevant progression26,38 but those
with JSN did8,9,39, the primary analytic focus was on comparing
rates of progression in KLG2 knees with JSN39 and with moderate
contra-lateral RKOA vs KLG2 knees with JSN without any contra-
lateral RKOA. The secondary analytic focus on comparing KLG2
knees with JSN and with moderate contra-lateral RKOA vs KLG3
knees that did not display contra-lateral RKOA.
As the primary measure of cartilage thickness change we
selected a non-location dependent measure of subregional carti-
lage change (i.e., OV one; the subregion with the greatest rate ofcartilage loss in each joint16,35), and as the secondary measure the
integral change in cartilage thickness throughout the entire FTJ.
Given the larger sample available, the primary focus was on OV one
and FTJ cartilage thickness loss over 1 year (n ¼ 837), and it was
checked whether results over 2 years were consistent in those that
also had 2-years follow-up data (n ¼ 487; n ¼ 350 were not
available for the 2-years follow-up period).
Differences in cartilage thickness change were compared within
strata of ipsi-lateral RKOA knee status (KLG2 with/without JSN,
KLG3) between groups of contra-lateral RKOA status using Krus-
kaleWallis testing and across strata and between different groups
of contra-lateral RKOA status using an unpaired Student's t-test.
Further we used generalized linear models with robust variance
estimator (Huber/White/Sandwich estimator) to calculate the odds
and the corresponding 95% conﬁdence intervals (CIs) with adjust-
ment for age, sex, BMI and MRI sequence (i.e., FLASH or DESS).
Contra-lateral radiographic knee status was used as independent
variable, whereas no contra-lateral RKOA was set as reference
group. Results were considered signiﬁcant at a level of P  0.05. As
supporting evidence, we also computed the number of progressors
in each stratum. A progressor was deﬁned as someone inwhom the
cartilage loss in either MFTC or LFTC (or both) exceeded a threshold
of cartilage loss derived from test-retest data on the FLASH (only
available in right knees) or DESS MRI sequence, using the smallest
detectable change (SDC) method40. This data was previously pub-
lished by our group and the values for being deﬁned as a progressor
are 102 mm for FLASHMFTC, 92 mm for FLASH LFTC, 111 mm for DESS
MFTC and 121 mm for DESS LFTC37.
Sensitivity analyses were performed to explore whether the
effect of the contra-lateral knee depended on its previous trauma
history. This was done to explore whether idiopathic contra-lateral
RKOA status was an indicator of intrinsic vulnerability, whereas
post-traumatic contra-lateral RKOA status was not. To this end, in a
separate analysis, we excluded all cases in which the contra-lateral
knee had a history of a self-reported knee trauma, leading to dif-
ﬁculties to walk for at least 1 week. This was the case for 224 (of
837) individuals with 1-year, and for 131 (of 487) individuals with
2-years of follow-up.
Results
Demographics
Of the 837 knees with 1-year follow-up data, 158 were KLG2
without JSN, 339 KLG2 with JSN, and 340 as KLG3 (Table I). Of those
that were KLG2with JSN, 81.7% (medial)/1.8% (lateral) had an OARSI
atlas JSN grade 1, and 0.3 (medial)/0% (lateral) had a grade 2 and
none had grade 3. Of those that were KLG3, 1.2 (medial)/0.6%
(lateral) had an OARSI atlas JSN grade of 1, and 74.4 (medial)/27.4%
(lateral) a grade 2 and none had grade 3 JSN. Further demographic
data are summarized in Table I.
Primary and secondary comparison
In KLG2 knees with JSN, the rate of maximum subregional
cartilage loss for those with moderate contra-lateral RKOA (KLG3 or
4) was 220 mm [95% CI 255, 184 mm] with a smaller Odds ratio
(OR) 0.95 [95% CI 0.91e0.98] (crude P ¼ 0.008) when compared to
those without contra-lateral RKOA (KLG0 or 1) (Table II). The rate of
subregional cartilage loss in KLG2 knees with JSN and moderate
contra-lateral RKOA (KLG3 or 4) was similar in magnitude, and not
signiﬁcantly different (P ¼ 0.61), to that in KLG 3 knees that did not
display contra-lateral RKOA (KLG0 or 1). Also, there was no signiﬁ-
cant difference to the rate of cartilage loss in all KLG3 knees inde-
pendent of their contra-lateral RKOA (KLG0 to 4) status (P ¼ 0.23).
Table II
One-year femorotibial cartilage thickness loss in knees with KLG 2, with and without JSN, and in KLG 3 knees, depending on contra-lateral RKOA status. Results are shown for
the subregional with the maximum cartilage thickness loss in each knee (OV one) and for the mean change in the (total) FTJ (n ¼ 837)
Contra-lateral RKOA status OV one FTJ
Mean change
(SD) mm
95% CI P
value*
OR** [95% CI] Mean change
(SD) mm
95% CI P
value*
OR** [95% CI]
No RKOA (n ¼ 47) 148 (65.1) 167; 128 1 (Ref.) 38.6 (137) 78.9; 1.73 1 (Ref.)
KLG 2 Ø JSN (n ¼ 158) Deﬁnite RKOA (n ¼ 89) 152 (151) 184; 120 0.56 0.99 [0.95e1.04] 29.1 (239) 79.5; 21.3 0.56 1.00 [0.94e1.08]
Moderate RKOA (n ¼ 22) 165 (168) 239; 90.1 0.98 [0.91e1.05] 53.1 (209) 146; 39.6 0.99 [0.91e1.10]
No RKOA (n ¼ 100) 164 (119) 187; 140 1 (Ref.) 43.9 (157) 75.1; 12.7 1 (Ref.)
KLG 2 þ JSN (n ¼ 339) Deﬁnite RKOA (n ¼ 148) 175 (136) 197; 152 0.01 0.99 [0.96e1.02] 35.2 (175) 63.6; 6.81 0.09 1.01 [0.97e1.05]
Moderate RKOA (n ¼ 91) 220 (170) 255; 184 0.95 [0.91e0.98] 98.7 (225) 146; 51.8 0.95 [0.90e1.00]
No RKOA (n ¼ 96) 232 (168) 266; 198 1 (Ref.) 110 (273) 166; 55 1 (Ref.)
KLG 3 (n ¼ 340) Deﬁnite RKOA (n ¼ 99) 256 (168) 290; 223 0.35 0.99 [0.95e1.04] 140 (212) 183; 98.1 0.44 0.98 [0.91e1.05]
Moderate RKOA (n ¼ 145) 242 (163) 269; 215 1.0 [0.96e1.05] 119 (212) 154; 84.6 0.99 [0.93e1.07]
No RKOA¼ KLG0 or 1; deﬁnite RKOA¼ KLG 2; moderate RKOA¼ KLG3 or 4; *unadjusted testing using KruskaleWallis-Test; **¼Generalized linear model with adjustment for
age, gender, BMI and MRI sequence.
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and with moderate contra-lateral RKOA (KLG3 or 4), the rate of loss
(98.7 mm [95% CI 145; 51.8]) was greater than in those without
contra-lateral RKOA (KLG0 or 1) reporting an odds of OR 0.95 [95%
CI 0.90e1.00] (crude P ¼ 0.051). Again, their rate of subregional
cartilage loss was not signiﬁcantly different to that in KLG 3 knees
without contra-lateral RKOA (KLG0 or 1; P ¼ 0.75) or when
compared to KLG3 knee independent of their contra-lateral RKOA
(KLG0 to 4) status (P ¼ 0.37).
The 2-year follow-up data were in general similar with obser-
vations made over 1 year follow-up (Table III). Over 1 year, the
proportion of “progressors” in KLG2 knees with JSN with moderate
contralateral RKOA (KLG3 or 4) was 5.9%, as opposed to 5.5% in
those with deﬁnite contra-lateral RKOA (KLG2) and only 3.9% in
those without contra-lateral RKOA (KLG0 or 1).
Other comparisons on contra-lateral knee effects
In KLG2 knees without JSN, the odds in those with moderate
contra-lateral RKOA (KLG3 or 4) was distinct smaller compared to
those without RKOA (KLG0 or 1) both at 1-year OR 0.98 [95% CI
0.91e1.05] and at 2-years follow-up OR 0.95 [95% CI 0.86e1.05]
(Tables II and III). The proportion of progressors in those with
moderate contra-lateral RKOA (KLG3 or 4) was only 1.0% as opposed
to 2.8% in those with deﬁnite contra-lateral RKOA (KLG2), and 1.7%
in those without contra-lateral RKOA (KLG0 or 1). In KLG3 knees,
the rates of change in those with moderate contra-lateral RKOA
(KLG3 or 4) appeared to be similar to those without contra-lateral
RKOA (KLG0 or 1), both over 1- and 2-year observation periods.
The proportion of progressors in KLG3 knees with moderate
contra-lateral RKOA (KLG3 or 4) was 10.4% as opposed to 7.4% inTable III
Two-year femorotibial cartilage thickness loss in knees with KLG 2, with and without JSN
the subregional with the maximum cartilage thickness loss in each knee (OV one) and f
Contra-lateral RKOA status OV one
Mean change
(SD) mm
95% CI P
va
No RKOA (n ¼ 30) 185 (98.1) 222; 149
KLG 2 Ø JSN (n ¼ 89) Deﬁnite RKOA (n ¼ 50) 166 (79.7) 189; 143 0.
Moderate RKOA (n ¼ 9) 231 (162) 356; 107
No RKOA (n ¼ 61) 191 (113) 220; 162
KLG 2 þ JSN (n ¼ 196) Deﬁnite RKOA (n ¼ 88) 213 (163) 248; 179 0.
Moderate RKOA (n ¼ 47) 241 (163) 288; 193
No RKOA (n ¼ 53) 327 (207) 385; 271
KLG 3 (n ¼ 202) Deﬁnite RKOA (n ¼ 68) 373 (246) 433; 313 0.
Moderate RKOA (n ¼ 81) 365 (241) 418; 312
No RKOA¼ KLG0 or 1; deﬁnite RKOA¼ KLG 2; moderate RKOA¼ KLG3 or 4; *unadjusted t
age, gender, BMI and MRI sequence.those with deﬁnite contra-lateral RKOA (KLG2), and 7.5% in those
without contra-lateral RKOA (KLG0 or 1).
Sensitivity analyses of trauma history
After excluding knees that had a trauma history in the contra-
lateral knee (n ¼ 224 at 1-year; n ¼ 131 at 2-years), observations
were generally consistent with those for the total sample, both over
one and over 2 years. In KLG2 knees with JSN, the rate of maximum
subregional cartilage loss was over the 1 year observational period
203 mm (95% CI 237; 169 mm) for those with moderate contra-
lateral RKOA (KLG3 or 4), 172 mm (95% CI 196, 149 mm) for
those with deﬁnite contra-lateral RKOA (KLG2) and 169 mm (95%
CI 197, 142 mm) for those without contra-lateral RKOA (KLG0 or
1) (P [across categories of contra-lateral RKOA] ¼ 0.06). The rate of
subregional cartilage loss in KLG2 knees with JSN and with mod-
erate contra-lateral RKOA (KLG3 or 4), was lower, compared to that
in KLG3 knees without contra-lateral RKOA (KLG0 or 1) (249 mm
[95% CI 286; 212 mm]; P ¼ 0.03).
Excluding additionally those with a trauma history in the ipsi-
lateral (investigated) knee (n ¼ 312) observations were consistent
with those for the total sample and for the sample without a
contra-lateral trauma exclusively, both over the one and over the
2-year observational period (data not shown).
Subregion with the greatest rate of longitudinal cartilage loss (OV
one)
The speciﬁc subregional location of the OV one within the FTJ
was over the 1 year period the central subregion of the lateral tibia
(cLT) for KLG2 knees without JSN independent of the contra-lateral, and in KLG 3 knees, depending on contra-lateral RKOA status. Results are shown for
or the mean change in the (total) FTJ (n ¼ 487)
FTJ
lue*
OR** [95% CI] Mean change
(SD) mm
95% CI P
value*
OR** [95% CI]
1 (Ref.) 59.3 (195) 132; 13.3 1 (Ref.)
79 1.01 [0.97e1.05] 26.6 (132) 64; 10.8 0.29 1.02 [0.95e1.10]
0.95 [0.86e1.05] 128 (210) 289; 33.7 0.96 [0.83e1.10]
1 (Ref.) 60.2 (172) 104; 16.1 1 (Ref.)
19 0.99 [0.95e1.04] 69.5 (226) 118; 21.6 0.43 0.99 [0.93e1.06]
0.97 [0.92e1.03] 116 (227) 183; 49 0.96 [0.89e1.04]
1 (Ref.) 199 (283) 277; 121 1 (Ref.)
57 0.96 [0.89e1.04] 262 (312) 337; 187 0.57 0.93 [0.84e1.04]
0.99 [0.91e1.07] 254 (308) 323; 186 0.96 [0.87e1.07]
esting using KruskaleWallis-Test; **¼Generalized linear model with adjustment for
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was the central subregion of the central (weightbearing) medial
femur (ccMF) for those with contra-lateral no and moderate RKAO
(KLG0 and KLG3 or 4), but cLT for those with contra-lateral deﬁnite
RKOA (KLG2). In KLG3 knees the OV one location was independent
of the contra-lateral RKOA status (KLG0-4) ccMF. The results for the
2 year observational period were similar to those observed at 1 year
(data not shown).
Discussion
To our knowledge, this is the ﬁrst study to explore a “progres-
sion” model of mild radiographic KOA (RKOA) based on contra-
lateral radiographic status. Speciﬁcally, we asked whether in
knees with KLG2 and JSN, the rate of cartilage loss was greater in
those with moderate contra-lateral RKOA than in those without
contra-lateral RKOA. We found that their rates of maximum sub-
regional cartilage thickness loss were signiﬁcantly greater, and
similar to those of KLG3 knees. In KLG2 knees without JSN, a similar
effect was seen, but did not reach statistical signiﬁcance, whereas in
KLG3 knees, contra-lateral knee status was not observed to be a
relevant indicator for subsequent cartilage loss. The observed ef-
fects were stronger supported by the femoro-tibial subregion with
the greatest longitudinal cartilage loss (OV one) than by the total
femoro-tibial joint cartilage measure, presumably due to the fact
that longitudinally cartilage thinning and thickening are simulta-
neously detected in knee OA progression41,42 but the clinical rele-
vance of the OV approach vs a region-speciﬁc analysis has not yet
been addressed thoroughly and deserves further exploration in
upcoming research studies.
To obtain sufﬁcient numbers of participants in each of the nine
strata investigated, we pooled longitudinal observations acquired
with a sagittal DESS13,14,43 or coronal FLASH MRI sequences26. This
may be viewed as a limitation, but previous studies have shown
that both protocols produce highly consistent results44,45. Further,
to account for potential differences in measurements of cartilage
thickness change between the protocols, we adjusted the gener-
alized linear models for “MR sequence”. Further, we performed a
post hoc analysis for the sequences used, without statistical sig-
niﬁcant impact on the output.
Another limitation of the current study is that biomechanical
factors such as altered gait patterns, reduced physical activity or
modiﬁed joint loading of the knee were not considered as con-
founding criteria for cartilage loss in the contra-lateral (investi-
gated) knee. Biomechanical effects may be linked to the severity of
contra-lateral RKOA and any beneﬁcial DMOAD effect might be
inﬂuenced by biomechanical abnormalities when not considered.
Therefore, future studies investigating the contra-lateral knee ef-
fect will have to include these biomechanical effects as confound-
ing criteria in their analyses. However, contra-lateral RKOA in this
study was not considered as a potential mechanical modiﬁer of
cartilage loss in the contra-lateral knee, but as a potential indicator
of intrinsic vulnerability.
Idiopathic knee OA is thought to be a bilateral disease and to
depend on intrinsic or extrinsic factors that have an impact on both
knees. Spector et al.18 were among the ﬁrst to establish that contra-
lateral RKOAwas a predictor of incident RKOA. A longitudinal study
with 14 years of follow-up showed that when one knee usually is
ﬁrst affected by RKAO, the contra-lateral one follows soon46. Davis
et al.19 showed that bi-lateral knee OA was more prevalent (5%)
than uni-lateral knee OA (2%), and that obesity was a two-fold
stronger predictor of bi-lateral OA than was knee injury. In
contrast, knee injury was shown to be a 4.7-fold stronger predictor
of uni-lateral OA than was obesity. For this reason, we performed a
sensitivity analysis, excluding study participants with a previoustrauma in the contra-lateral knee. Yet, this analysis was consistent
with results obtained in the total sample.
Since change from a normal joint to end-stage RKOA represents
a continuum47, it is reasonable to assume that a relationship be-
tween contra-lateral knee status and structural progression (i.e.,
cartilage loss) in the target knee may also exist at later stages of
RKOA. Our results show that this is the case, and that at least KLG2
knees with moderate contra-lateral RKOA generally show greater
progression rates that those without contra-lateral RKOA. We have
no deﬁnite explanation, why this was observed in KLG2, but not in
KLG3 knees, and why the effect only was speciﬁcally statistically
signiﬁcant in KLG2 knees with JSN. It may be that KLG2 knees with
JSN are at a transitional phase where cartilage tissue loss starts, and
that this distinct transitional phase is characterized by a higher
“vulnerability” towards OA progression. This vulnerability is
potentially indicated by moderate RKOA (KLG3 or 4) in the contra-
lateral knee and it appears to be more relevant at this stage
compared to earlier or later phases of the disease. Although the
clinical signiﬁcance of cartilage tissue loss remains to be explored,
recent studies have found that cartilage loss was signiﬁcantly
greater in knees prior to knee replacement (considered a “hard”
clinical endpoint) than in knees with the same KLG who did not
move on to replacement during this observation period48,49.
The concrete aim of the study was to test whether sufﬁcient
rates of cartilage loss can be observed in knees at a relatively mild
radiographic status over short (i.e., one year) observation periods
that are acceptable for DMOAD trials. The observed rates of change
display a smaller statistical differences in the respective strata after
adjustment for co-factors and might be of minor relevance for daily
clinical use, but these results highlight a clear trend: the rates of
change in KLG2 knees with JSN and with moderate contra-lateral
RKOA (KLG3 or 4) are not signiﬁcantly different to those
commonly observed in KLG3 knees, although these (KLG2) knees
are still at a “relatively”mild radiographic stage, with only little JSN
being present. Mild disease stages are thought to be more
amendable to disease modiﬁcation8e10,50 and it is plausible to
intervene therapeutically at a stage at which cartilage can still be
preserved. However, the dilemma is that to demonstrate the effect
of a DMOAD to stop cartilage loss in unselected KLG2 knees requires
extensive follow-up times, given the small rates of cartilage loss
occurring in KLG2 knees, particularly in those without JSN26,38.
Therefore, KLG2 knees with JSN and with moderate contra-lateral
ROA may represent a unique opportunity to test anti-catabolic
DMOADs over a more reasonable observation period. This, of
course, requires an elaborate recruitment process: To test whether
this was feasible, we analyzed the OAI “progression cohort”, i.e.,
subjects that had at least one knee with frequent symptoms and
deﬁnite RKOA as scored for recruitment purposes by the site in-
vestigators. Of these 2780 knees (from 1390 individuals), 13.3%
were KLG2 without JSN, 24.3% KLG2 with JSN, 28.1% KLG3, and 8.3%
KLG4. Of those that were KLG2 with JSN, only about one third (i.e.,
7.9% of the entire cohort) also had moderate contra-lateral RKOA.
This indicates that the recruitment effort for a trial studying only
KLG2 knees with JSN with moderate contra-lateral RKOA would be
relatively high and that almost 1300 patients would have to be
screened by radiography, for 100 to be ﬁnally enrolled. However,
this may be rewarded by an early RKOA model, in which cartilage
loss can be observed (and potentially modiﬁed) over relatively
short (i.e., one year follow-up) periods. Subsequent studies will be
required to demonstrate the effect of this selection process and to
develop the idea of the contra-lateral knee effect further.
In conclusion, we show that KLG2 knees, and particularly KLG2
knees with JSN, moderate contra-lateral RKOA is associated with
greater rates of future cartilage loss compared with KLG2 knees
without contra-lateral RKOA. KLG2 knees with JSN and with
Fig. 1. 1-year and 2-year change in cartilage thickness in the OV one location in knees with KLG 2 and 3 and with and without JSN; (according to the OARSI atlas) having no (KLG0 or
1), deﬁnite (KLG2) or moderate (KLG3 or 4) contra-lateral RKOA. Please note that changes are total changes observed in the respective observational period: 1-year and 2-years.
Fig. 2. 1-year and 2-year change in cartilage thickness in the (total) FTJ in knees with KLG 2 and with and without JSN; (according to the OARSI atlas) and KLG3 having no (KLG0 or
1), deﬁnite (KLG2) or moderate (KLG3 or 4) contra-lateral RKOA. Please note that changes are total changes observed in the respective observational period: 1-year and 2-years.
S. Cotofana et al. / Osteoarthritis and Cartilage 22 (2014) 2059e20662064moderate contra-lateral RKOA, display rates of femorotibial carti-
lage loss similar to KLG3 knees, despite being at a mild stage of
radiographic disease. They may therefore provide a unique oppor-
tunity for recruitment in clinical trials that explore the efﬁcacy of
anti-catabolic DMOADs on structural progression but the clinical
relevance of the presented ﬁndings needs to be explored further.
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